Polymeric treatment compositions

Patent metadata

Field	Value
Publication number	US-9937201-B2
Application number	US-201615142395-A
Country	US
Kind code	B2
Filing date	Apr 29, 2016
Priority date	Jun 14, 2012
Publication date	Apr 10, 2018
Grant date	Apr 10, 2018

Abstract

Compositions are described comprising a polymer; a non-physiological pH solution; and a visualization agent; wherein the polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

First claim

We claim:

1. A method of delivering a composition comprising:
injecting through a delivery device into a location with physiological pH environment a liquid embolic composition comprising a biocompatible polymer, an aqueous solution with a non-physiological pH, and a visualization agent, wherein the visualization agent is an iodinated compound, barium sulfate tantalum, superparamagnetic iron oxide, gadolinium molecules, or a combination thereof,
wherein the biocompatible polymer is soluble in the aqueous solution and precipitates when it reaches the physiological pH and wherein the biocompatible polymer comprises:
a first monomer selected from a group consisting of aminopropyl methacrylamide, aminoethyl methacrylamide, N-(3-methylphridine)acrylamide, N-(2-(4-aminophenyl)ethylacrylamide, N-(4-aminobenzyl)acrylamide, N-(2-4-imidazolyl)ethyl)acrylamide, and combinations thereof; and
a second monomer selected from a group consisting of t-butyl acrylate, t-butyl acrylamide, n-octyl methacrylate, methyl methacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, hydroxypropyl methacrylate, hydroxybutyl methacrylate, derivatives thereof, or combinations thereof.

2. The method of claim 1 , wherein the visualization agent is a particulate.

3. The method of claim 1 , wherein the visualization agent has a concentration of about 5% to about 65%.

4. The method of claim 1 , wherein the biocompatible polymer is a reaction product of three different monomers.

5. The method of claim 1 , wherein the aqueous solution with a non-physiological pH is water.

6. The method of claim 1 , wherein the non-physiological pH solution has a pH of less than about 5.

7. The method of claim 1 , wherein the non-physiological pH solution has a pH of greater than about 8.

8. The method of claim 1 , wherein the biocompatible polymer has a concentration of about 1% w/w to about 35% w/w.

9. A method of treating a vascular disorder comprising
providing a liquid embolic composition comprising a biocompatible polymer, an aqueous solution with a non-physiological pH, and a visualization agent, wherein the visualization agent is an iodinated compound, barium sulfate tantalum, superparamagnetic iron oxide, gadolinium molecules, or a combination thereof and the biocompatible polymer is soluble in the aqueous solution and insoluble in a physiological pH and comprises:
a first monomer selected from a group consisting of aminopropyl methacrylamide, aminoethyl methacrylamide, N-(3-methylphridine)acrylamide, N-(2-(4-aminophenyl)ethylacrylamide, N-(4-aminobenzyl)acrylamide, N-(2-4-imidazolyl)ethyl)acrylamide, and combinations thereof; and
a second monomer selected from a group consisting of t-butyl acrylate, t-butyl acrylamide, n-octyl methacrylate, methyl methacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, hydroxypropyl methacrylate, hydroxybutyl methacrylate, derivatives thereof, or combinations thereof;
inserting a delivery device into a vessel;
guiding the delivery device to an area in need of treatment wherein the area has a physiological pH;
injecting the liquid embolic polymer composition through the delivery device into the vessel at the area in need of treatment thereby immediately precipitating the biocompatible polymer and forming a solid polymeric mass; and
treating the vascular condition.

10. The method of claim 9 , wherein the visualization agent is a particulate.

11. The method of claim 9 , wherein the visualization agent has a concentration of about 5% to about 65%.

12. The method of claim 9 , wherein the biocompatible polymer is a reaction product of three different monomers.

13. The method of claim 9 , wherein the aqueous solution with a non-physiological pH is water.

14. The method of claim 9 , wherein the non-physiological pH solution has a pH of less than about 5.

15. The method of claim 9 , wherein the non-physiological pH solution has a pH of greater than about 8.

16. The method of claim 9 , wherein the biocompatible polymer has a concentration of about 1% w/w to about 35% w/w.

Assignees

• Microvention Inc

Inventors

• Cruise Gregory M
• Constant Michael J
• Garretson Joshua

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K47/32

  Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} · CPC title

• A61K31/78

  of acrylic acid or derivatives thereof · CPC title

• A61L24/046

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L24/043 takes precedence) · CPC title

• A61L2430/36

  for embolization or occlusion, e.g. vaso-occlusive compositions or devices · CPC title